

## ASX Announcement

14 March 2025

The Manager  
Market Announcements Platform  
Australian Securities Exchange Limited

### **NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)**

This notice is given by ReNerve Limited (ASX:RNV) (ReNerve or the Company) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Act).

ReNerve has issued 666,212 fully paid ordinary shares (New Shares) at an issue price of \$0.1489 per New Share pursuant to the Appendix 2A announced to ASX on 14 March 2025.

For the purpose of section 708A(6) of the Act, the Company hereby notifies that:

- a) the Company issued the New Shares without disclosure to investors under Part 6D.2 of the Act;
- b) this notice is given under section 708A(5)(e) of the Act;
- c) as at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (ii) sections 674 of the Act;
- d) as at the date of this notice, there is no information that is 'excluded information' of the type referred to in section 708A(7) or section 708A(8) of the Act that is required to be disclosed pursuant to section 708A(6)(e) of the Act.

**This announcement has been approved for release by the Company's Board of Directors.**

**- ENDS -**

**For further information and enquiries, please contact:**

**Dr Julian Chick**  
CEO & Managing Director  
ReNerve Ltd  
+61 (03) 9482 3940  
[info@renerve.com.au](mailto:info@renerve.com.au)

**Jane Morgan**  
Investor & Media Relations  
Jane Morgan Management  
+61 (0) 405 555 618  
[info@janemorganmanagement.com.au](mailto:info@janemorganmanagement.com.au)



+61 (03) 9482 3940



157 Heidelberg Rd,  
Northcote, VIC 3070



[www.renerve.com.au](http://www.renerve.com.au)

## About ReNerve Limited

ReNerve Limited (ASX:RNV) is a medical device company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs for patients with peripheral nerve damage – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry's Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff.

For personal use only